ZURA
Income statement / Annual
Last year (2024), Zura Bio Limited's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Zura Bio Limited's net income was -$45.39 M.
See Zura Bio Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$24.40 M
|
$44.00 M
|
$23.69 M
|
$0.00
|
| General & Administrative Expenses |
$30.79 M
|
$0.00
|
$2.68 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$30.79 M
|
$18.64 M
|
$2.68 M
|
$1.09 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$55.19 M
|
$62.64 M
|
$2.68 M
|
$1.09 M
|
| Cost And Expenses |
$0.00
|
$62.64 M
|
$2.68 M
|
$1.09 M
|
| Interest Income |
-$8.00 M
|
$2.19 M
|
$570.00
|
$23,479.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$167,895.00
|
$228,485.00
|
$236,558.00
|
| EBITDA |
-$55.19 M |
-$60.56 M |
-$27.33 M |
$8.42 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.79 M
|
$2.08 M
|
-$24.66 M
|
$9.51 M
|
| Income Before Tax |
-$52.40 M
|
-$60.56 M
|
$3.55 M
|
$8.42 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$7.02 M
|
-$203,000.00
|
-$570.00
|
-$236,558.00
|
| Net Income |
-$45.39 M
|
-$60.36 M
|
$3.55 M
|
$8.42 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
| EPS |
-0.6 |
-2.09 |
0.21 |
0.4 |
| EPS Diluted |
-0.6 |
-2.09 |
0.21 |
0.4 |
| Weighted Average Shares Out |
$75.07 M
|
$33.06 M
|
$17.25 M
|
$17.25 M
|
| Weighted Average Shares Out Diluted |
$75.07 M
|
$33.06 M
|
$17.25 M
|
$17.25 M
|
| Link |
|
|
|
|
